Quality risk analysis in a cGMP environment: multiple models for comprehensive failure mode identification during the computer system lifecycle

Author： Gervais Brian   D’Arcy Deirdre M.  

Publisher： Informa Healthcare

ISSN： 0363-9045

Source： Drug Development and Industrial Pharmacy, Vol.40, Iss.1, 2014-01, pp. : 46-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

cGMP signalling beyond nitric oxide

By Mayer B.   Koesling D.  

Trends in Pharmacological Sciences, Vol. 22, Iss. 11, 2001-11 ,pp. : 546-548

Elsevier

Access to resources Recommend Favorite

cGMP Signaling, Phosphodiesterases and Major Depressive Disorder

By  

Current Neuropharmacology, Vol. 9, Iss. 4, 2011-12 ,pp. : 715-727

Bentham Science Publishers

Access to resources Recommend Favorite

Negative functional effects of cGMP mediated by cGMP protein kinase are reduced in T 4 cardiac myocytes

By Engel S.   Yan L.   Weiss H.   Scholz P.  

European Journal of Pharmacology, Vol. 421, Iss. 1, 2001-06 ,pp. : 23-30

Elsevier

Access to resources Recommend Favorite

Cellular Efflux of cAMP and cGMP - A Question about Selectivity

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 8, 2009-07 ,pp. : 1009-1013

Bentham Science Publishers

Access to resources Recommend Favorite

The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation

By Kruuse C.   Rybalkin S.D.   Khurana T.S.   Jansen-Olesen I.   Olesen J.   Edvinsson L.  

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 55-65

Elsevier

Access to resources Recommend Favorite